Table 3.
Number of cases where laboratory values exceed the laboratory reference range at least once
| Infliximab |
Vedolizumab |
|||
|---|---|---|---|---|
| CD (Nf = 31; Nm = 36) | UC (Nf = 17; Nm = 15) | CD (Nf = 10; Nm = 5) | UC (Nf = 6; Nm = 1) | |
| CK | ||||
| Female >157 U/L, n (%) | 16 (51.6) | 7 (41.2) | 4 (40.0) | 2 (33.3) |
| Male >200 U/L, n (%) | 25 (69.4) | 11 (73.3) | 2 (40.0) | 9 (81.8) |
| LDH | ||||
| Female >214 U/L, n (%) | 27 (87.1) | 13 (76.5) | 9 (90.0) | 6 (100) |
| Male >225 U/L, n (%) | 30 (83.3) | 15 (100) | 4 (80.0) | 7 (63.6) |
| CRP | ||||
| >10 mg/L, n (%) | 46 (68.7) | 17 (53.1) | 9 (60.0) | 8 (47.1) |
| FCal | ||||
| >50 µg/L, n (%) | 54 (80.6) | 24 (75.0) | 7 (46.7) | 9 (52.9) |
CK, creatine kinase; LDH, lactate dehydrogenase; CRP, C-reactive protein; FCal, fecal calprotectin; CD, Crohn's disease; UC, ulcerative colitis.